Outset Medical (NASDAQ: OM) got a nice boost today after reporting preliminary fourth-quarter and full-year 2025 financial results.

‍

Take a look …

‍

For Q4, 2005, revenue clocked in at around $28.9 million, bringing its full-year total to about $119.5 million. That’s a 5 % increase over 2024. 

‍

This performance places the company at the high end of its previously announced revenue guidance range, signaling a stabilization of sales trends and solid commercial traction for its Tablo® Hemodialysis System, which is an all-in-one dialysis machine designed to make kidney dialysis simpler, more flexible, and more accessible for both healthcare providers and patients. 

‍

It’s actually pretty ingenious, as it combines advanced automation, data connectivity, and an easy-to-use interface that works across multiple care settings.

‍

Alongside revenue growth, Outset’s financials showed significant operational progress: its net cash used in operations for 2025 was below $50 million, less than half of 2024’s cash burn. 

‍

At year-end, the company reported a strong cash position of about $173 million, giving it a runway into 2026 with lower refinancing risk. This combination of revenue growth and improved cash efficiency reassured investors of Outset’s financial sustainability as it continues to expand Tablo installations.

‍

Outset noted that more than 1,000 healthcare sites had adopted its Tablo system by the end of 2025, with roughly 1 million treatments performed annually. That broad installed base – especially in both hospital and outpatient settings – supports recurring revenue from consumables and services, which is a valued characteristic for medical device stocks.

‍

To be sure, Outset’s stock has been highly volatile in recent years due to a heavy cash burn and past sales disruptions. But today’s move suggests that investors are placing greater weight on operational progress and expanding adoption of its Tablo platform, positioning the company for potential growth in 2026.

‍

Bottom line: Outset Medical’s stock was up big today because the company posted better-than-expected 2025 revenue, demonstrated improved financial discipline, and underscored broader customer adoption of its dialysis technology. All factors that helped rebuild investor confidence.  Something it desperately needed.

‍